Mikhail Eydelman - 05 Dec 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, GEN COUNSEL & CORP SEC
Signature
Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
05 Dec 2024
Net transactions value
-$394,112
Form type
4
Filing time
09 Dec 2024, 18:28:05 UTC
Previous filing
08 Nov 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Gift $0 -110 -0.38% $0.000000 28,697 05 Dec 2024 Direct F1, F2
transaction PCVX Common Stock Options Exercise $107,050 +5,000 +17% $21.41 33,697 05 Dec 2024 Direct
transaction PCVX Common Stock Sale $129,384 -1,435 -4.3% $90.16 32,262 05 Dec 2024 Direct F3, F4
transaction PCVX Common Stock Sale $292,004 -3,177 -9.8% $91.91 29,085 05 Dec 2024 Direct F3, F5
transaction PCVX Common Stock Sale $36,046 -388 -1.3% $92.90 28,697 05 Dec 2024 Direct F3, F6
transaction PCVX Common Stock Tax liability $43,728 -475 -1.7% $92.06 28,222 09 Dec 2024 Direct F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5,000 -3% $0.000000 159,497 05 Dec 2024 Common Stock 5,000 $21.41 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a bona fide gift of the Issuer's Common Stock to a non-profit educational institution.
F2 Includes 184 shares acquired on November 15, 2024 under the Issuer's Employee Stock Purchase Plan.
F3 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $89.655 to $90.645. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $91.265 to $92.175. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $92.29 to $93.11. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F8 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.